Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Expands Selzentry Indication, But Ties Use To Screening With "Highly Sensitive" Assay

This article was originally published in The Pink Sheet Daily

Executive Summary

Labeling for additional indication for newly diagnosed patients cautions about higher virologic failure in treatment-naïve patients receiving maraviroc during the clinical trial.
Advertisement

Related Content

Tibotec Files NNRTI Rilpivirine, Part Of Gilead's New Combo For HIV
Tibotec Files NNRTI Rilpivirine, Part Of Gilead's New Combo For HIV
Tibotec Files Once-Daily NNRTI Rilpivirine, Part Of Gilead's New Combo For HIV
Tibotec Files Once-Daily NNRTI Rilpivirine, Part Of Gilead's New Combo For HIV
Regulatory Updates, In Brief
Regulatory Updates, In Brief
GSK And Pfizer Join Forces In New HIV-Focused Venture
Selzentry Patient Population Needs Further Definition, Advisory Panel Urges
Selzentry Faces Assay Challenge Even After Advisory Committee Thumbs Up
Selzentry Faces Assay Challenge Even After Advisory Committee Thumbs Up

Topics

Advertisement
UsernamePublicRestriction

Register

PS068804

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel